Tiffani Hamilton, MD
Dermatology · Alpharetta, GANPI 1710931027
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Galderma Laboratories, L.p. at 40.0% of the total. Reporting peaked in 2020 at $9,864 and has fallen 85.3% since, to $1,452 in 2025. Among dermatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 574 payments — averaging $35.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$8K
- AbbVie$5K
- Novartis$1K
- Sanofi$963
- UCB, Inc.$779
- Johnson & Johnson$705
- plus $3K from 27 others
Across 304 payments — averaging $10,869 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.1M
- Amgen$652K
- AbbVie$489K
- Janssen Research & Development, LLC$483K
- UCB SA$265K
- Boehringer Ingelheim$229K
- plus $118K from 8 others
What the payments were for
- Consulting fees$2,29611%
- Speaking & faculty fees$6,57532%
- Food & beverage$11,57956%
- Education$790%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 68 | $8,217 |
| AbbVie(2 entities) | 133 | $5,096 |
| Novartis | 67 | $1,371 |
| Sanofi | 43 | $963 |
| UCB, Inc. | 36 | $779 |
| Johnson & Johnson | 44 | $705 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 40 | $576 |
| Lilly USA, LLC | 33 | $559 |
| E.r. Squibb & Sons, L.L.C. | 20 | $364 |
| Regeneron Healthcare Solutions, Inc. | 13 | $318 |
| Sun Pharmaceutical Industries Inc. | 17 | $302 |
| Pfizer | 12 | $240 |
| Revance Therapeutics, Inc. | 3 | $163 |
| Paratek Pharmaceuticals, Inc. | 7 | $157 |
| Dermavant Sciences, Inc. | 4 | $83 |
| Organon | 4 | $82 |
| Mayne Pharma Commercial LLC | 4 | $74 |
| Journey Medical Corporation | 4 | $71 |
| Boehringer Ingelheim | 3 | $61 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Fidia Pharma USA Inc. | 2 | $38 |
| VYNE Pharmaceuticals Inc. | 2 | $37 |
| Aclaris Therapeutics, Inc. | 2 | $29 |
| EPI Health, LLC | 1 | $27 |
| Sanofi Pasteur Inc. | 2 | $26 |
| LEO Pharma Inc. | 1 | $26 |
| Tactile Systems Technology Inc | 1 | $19 |
| Convatec Inc. | 1 | $19 |
| Biofrontera Inc. | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Merck | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Mission Pharmacal Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$2,213
- Rinvoq$223
- Skyrizi$215
- DAXXIFY$110
How this compares
$20,528 in reported general payments places this provider in the 90th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyriziRisankizumab-Rzaa | 12 | $259,525 |
| EnbrelEtanercept | 25 | $186,810 |
| Taltz SyringeIxekizumab | 13 | $82,532 |
| Clobetasol Propionate | 38 | $1,785 |
| ValacyclovirValacyclovir Hcl | 52 | $1,548 |
| Imiquimod | 12 | $1,436 |
| Doxycycline Hyclate | 22 | $1,219 |
| Dutasteride | 36 | $827 |
| Triamcinolone Acetonide | 39 | $443 |
| Minoxidil | 30 | $355 |
| Finasteride | 17 | $190 |
| Spironolactone | 16 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi | $5,096 | $259,52512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 345 dermatology providers in Georgia.
Other dermatology in Alpharetta
- Chynna JohnsonAlpharetta$60K
- Firas HougeirDouglasville$3.1M
- David CohenMacon$2.9M
- Zakiya RiceAtlanta$1.1M
- Joseph PayneAtlanta$711K
- Jonathan WeissSnellville$692K
- Jamie WeismanAtlanta$620K
- Mack RachalAtlanta$260K
- Tiffany Clay-RamseyMarietta$207K
- Jessica MercerSnellville$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.